Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Merck & Co Inc. (MRK)
Nine Major Drugmakers Agree To Lower Drug Prices Through TrumpRx Initiative
12/19/2025 8:45:40 PM
Merck Reaches Agreement With U.S. Government To Expand Access To Medicines And Lower Costs For Americans
12/19/2025 4:13:30 PM
Merck's CAPVAXIVE Added To Publicly Funded Adult Immunization Program In Saskatchewan
12/8/2025 7:15:33 AM
Merck’s CAPVAXIVE Added To Saskatchewan’s Publicly Funded Adult Immunization Program
12/8/2025 7:05:23 AM
Merck Unit Gets FDA Conditional Approval For EXZOLT CATTLE-CA1 To Treat Key Cattle Parasites
12/4/2025 8:29:15 PM
Formycon, MS Pharma In Deal To Commercialize Keytruda Biosimilar Candidate FYB206 In MENA Region
12/4/2025 12:46:33 AM
Antengene: China Approves IND For ATG-022 Combo Study With Merck's KEYTRUDA
12/2/2025 5:20:04 AM
Merck Presents New Alzheimer's Candidates Data At CTAD 2025 Today
12/1/2025 10:43:22 AM
FDA Approves First And Only ADC And PD-1 Inhibitor Regimen For Certain Patients With Bladder Cancer
11/24/2025 2:44:57 AM
Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
11/21/2025 11:01:01 PM
Merck Urges Shareholders To Reject Unsolicited Mini-Tender Offer From Tutanota LLC
11/21/2025 10:28:10 PM
Merck Recommends Rejection Of Tutanota's $65.00/shr Mini-Tender Offer
11/21/2025 8:39:34 PM
FDA Approves Merck’s KEYTRUDA With Padcev As First PD-1 + ADC Option For Cisplatin-Ineligible MIBC Patients
11/21/2025 4:40:55 PM
Merck Canada And Pan-Canadian Pharmaceutical Alliance Complete Negotiations For WINREVAIR
11/20/2025 7:21:58 AM
Merck Declares Quarterly Dividend Of $0.85/share, Payable Jan. 8/ Record Dec. 15
11/18/2025 11:47:37 AM
Merck's WINREVAIR Meets Primary Endpoint In Phase 2 CADENCE Study, Stock Up In Pre-Market
11/18/2025 7:32:22 AM
Merck Announces Positive Topline Results From Phase 2 CADENCE Study Of WINREVAIR
11/18/2025 6:48:06 AM
Merck To Acquire Cidara For $221.50/shr
11/14/2025 7:15:17 AM
Merck To Acquire Cidara For $221.50/Shr Cash For Transaction Value Of About $9.2 Bln
11/14/2025 6:50:13 AM
Cidara Therapeutics Shares Surge In After-Hours On Report Of Nearing Merck Deal
11/13/2025 9:46:00 PM
1
2
3
Next
»